Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993288 | 0.86 | MCHR1 (0.57) | MCHR1CHRM1HTR2ALTA4HPPARG | |
| SCHEMBL4591781 | 0.86 | MCHR1 (0.52) | MCHR1CHRM1HTR2ALTA4HCYSLTR1 | |
| SCHEMBL4592135 | 0.82 | MCHR1 (0.53) | MCHR1CHRM1HTR2ALTA4HBCAT2 | |
| SCHEMBL10269398 | 0.76 | LTA4H (0.67) | LTA4HPPARGFFAR1ALDH1A1RECQL | |
| SCHEMBL8618329 | 0.76 | LTA4H (0.67) | LTA4HCYSLTR1FFAR1ALDH1A1RECQL | |
| SCHEMBL4591085 | 0.76 | BCAT2 (0.53) | MCHR1CHRM1HTR2ALTA4HBCAT2 | |
| SCHEMBL2998965 | 0.75 | MCHR1 (0.47) | MCHR1CHRM1HTR2ALTA4HPPARG | |
| SCHEMBL3009333 | 0.75 | LTA4H (0.65) | MCHR1CHRM1HTR2ALTA4H | |
| SCHEMBL8392892 | 0.75 | FFAR1 (0.68) | LTA4HPPARGFFAR1 | |
| SCHEMBL8390278 | 0.74 | LTA4H (0.69) | LTA4HCYSLTR1FFAR1ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943231-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MCHR1 1/4885CHRM1 84/4885HTR2A 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.